Clinical Study of HRS-2129 for Acute Gouty Arthritis
ConditionAcute Gouty Arthritis
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorShandong Suncadia Medicine Co., Ltd.
About this trial
The study is being conducted to evaluate the safety, and efficacy of HRS-2129 for acute gouty arthritis. To explore the reasonable dosage of HRS-2129 for acute gouty arthritis.
Eligibility criteria
Qualifiers
Able and willing to provide a written informed consent
Subjects requiring Acute gouty arthritis
Target joint VAS pain score ≥ 50 mm (screening)
Disqualifiers
Subjects with a history of severe allergies
Subjects with nervous system disease
Subjects with a history of mental illness
Subjects with abnormal liver and renal function
Trial design
Treatments tested in this trial
- HRS-2129 Tablet
- HRS-2129 Tablet
- Placebo
Treatment groups
90 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov